finance.yahoo.comAUG 251 min read$BHC

Bausch + Lomb Advances Dry Eye Drug to Phase III as Pain Candidate Hits Phase Ib Goal

Bausch + Lomb will advance its dry eye drug to Phase III trials, focusing on day 15 results after missing day 29 goals. Its pain treatment, BL1332, met Phase Ib goals, reducing pain intensity and duration. The company plans to consult with the FDA.

Original reporting

finance.yahoo.com

Published Aug 25, 2026, 1:01 AM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Aug 25, 2026, 9:22 AM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

Bausch + Lomb Advances Dry Eye Drug to Phase III as Pain Candidate Hits Phase Ib Goal — source image — Source · finance.yahoo.com

Decision brief

The 30-second read

$BHCBullishMed

Why it matters

The trial data provides fresh material for valuation models and may trigger analyst upgrades.

Market read

New clinical data could influence biotech equities and sector sentiment.

What to watch

Regulatory timeline and competitive pipeline could moderate upside.

Relevance 8/10Novelty 8/10Timing: today

Background

Bausch + Lomb is a division of Bausch Health Companies, focusing on eye care products.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$BHCBullishHigh confidence

Context

Bausch + Lomb announced its dry eye drug advanced to Phase III and reported Phase Ib pain reduction results.

Expected impact

Potential upside as investors price in later-stage trial success.

Evidence & confidence

Phase III advancement and strong Phase Ib pain reduction are material clinical milestones for a listed biotech.

Market effects

Sector

May lift other dry eye and ophthalmology drug developers.

Regional

U.S. biotech sector could see modest gains.

Global

Limited to pharma/biotech investors.

Counterpoint

What could challenge this read

Phase III success is not guaranteed; earlier endpoint miss at day 29 could signal risk.

Key entities

company
Bausch + Lomb
Eye care division of Bausch Health Companies Inc.

Read at source ← All news

AUG 25

$BHCMedAI 8/10

Bausch + Lomb progresses dry eye candidate to Phase III despite mixed data

Bausch + Lomb will advance its dry eye treatment to Phase III despite mixed Phase II results. The eye drop, combining lifitegrast and perfluorohexyloctane, missed its primary endpoint but showed statistical significance in a secondary analysis. The company also progresses BL1332 to Phase II after positive pain reduction data in a Phase Ib trial.

clinicaltrialsarena.com2 min

AUG 10

$BHCMedAI 8/10

Why Bausch Health Companies Stock Skyrocketed by Almost 40% Last Month

Bausch Health Companies (BHC) shares rose nearly 40% in July after a Canada regulatory update and a beat-and-raise quarter. Prokedi was added to Quebec’s formulary. In Q2, revenue and adjusted results improved, with adjusted EPS $1.26 vs $1.23 expected, and net income $476M. Bausch raised 2026 revenue to $10.79B-$11.04B and adjusted EBITDA to $4.05B-$4.18B.

fool.com6 min

AUG 9

$BHCMedAI 9/10

Bausch Health (BHC) Q2 2026 Earnings Call Transcript

Bausch Health (NYSE:BHC) reported Q2 2026 results excluding Bausch + Lomb: revenue $1.458B (+16%), adjusted EBITDA $865M (+28%), margin 59.3% (+530 bps), and adjusted operating cash flow $471M. Net debt fell to $13.7B. Full-year 2026 guidance was raised. Headwinds include Aplenzin LOE and CMS rebate impacts.

aol.com6 min

AUG 2

$BHCMed

BHC Surges As Bausch Health Crushes Q2 And Lifts 2026 Outlook

Bausch Health Companies Inc. (BHC) shares rose about 13.6% after Q2 results and an improved 2026 outlook, according to the article. Q2 non-GAAP EPS was $1.26 vs $1.01 consensus, revenue $2.85B vs $2.66B. The company reported free cash flow around $593M and lifted 2026 guidance to revenue $10.79B-$11.04B and adjusted EBITDA $4.05B-$4.175B.

stockstotrade.com6 min

AUG 1

$BHCHighAI 9/10

BHC Soars As Bausch Health Earnings Beat Triggers Repricing

Bausch Health Companies Inc. (BHC) shares rose about 13.6% after Q2 results beat expectations and 2026 guidance was raised, according to the article. Q2 revenue was about $2.85B vs $2.66B expected, non-GAAP EPS $1.26 vs $1.01, with $670M operating cash flow and $593M free cash flow. The stock moved from the $4s to near $6.9.